Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study - Top-Institutions - MDSpire

Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study

  • By

  • Tao Zhang

  • Xue Li

  • Junsong Zeng

  • Maosen Xu

  • Yan Tie

  • June 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University Hospital Essen
    University Hospital Essen

    Essen, North Rhine-Westphalia

    Key Differentiators

    • Urology
    • Nuclear Medicine

  • #2

    West China Hospital
    West China Hospital

    Chengdu, Sichuan

    Key Differentiators

    • Urology

  • #3

    South Australian Prostate Cancer Clinical Outcome Collaborative
    South Australian Prostate Cancer Clinical Outcome Collaborative

    Adelaide, South Australia

    Key Differentiators

    • Urology

Original Source(s)

Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study

  • by Tao Zhang, Xue Li, Junsong Zeng, Maosen Xu, Yan Tie

  • June 30, 2026

Related Content

ESMO Breast Cancer 2026 Highlights: Saci-IO HR+

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Fractionated stereotactic radiotherapy (fSRT) for symptomatic WHO grade 1 cavernous sinus meningiomas: long-term local control, clinical response, and toxicity outcomes

Metaplastic breast carcinoma with osteosarcomatous differentiation: a case report